With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010
With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
For Dx shops developing pharmacogenomic tests without big pharma's help, Medco says it can offer a better value proposition when it comes to driving adoption and reimbursement for their tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter - Conference Discussion Questions Big Pharma's True Motivations for Pursuing Personalized Medicine
December 2, 2009 / Pharmacogenomics Reporter - Fate of Medco's Personalized Medicine Programs Uncertain Under Express Scripts' Acquisition Plan
July 27, 2011 / Pharmacogenomics Reporter